Hainan Hualon Pharmaceutical

What Hainan Hualon Pharmaceutical does

Hainan Hualon Pharmaceutical Co., Ltd. (海南皇隆制药股份有限公司) is a privately-held Chinese pharmaceutical manufacturer headquartered in Haikou National High-tech Industrial Development Zone, Hainan Province. Recognized as a National Torch Plan Key High-tech Enterprise and Hainan Province Industrial Leading Enterprise, the company develops, manufactures, and distributes generic drugs across four formulation formats: oral, injection, topical/external, and inhalation. Its therapeutic focus centers on cardiovascular and cerebrovascular diseases, diabetes (the "three highs" — hypertension, hyperlipidemia, hyperglycemia), anti-infectives, dermatology, and pain management. The company has 8 generic drug products that have passed or are equivalent to passing China's generic drug consistency evaluations, holds 31 granted patents (including 25 invention patents and 4 international patents), and maintains a pipeline of approximately 30 formulation products in various development stages.

The company operates a dedicated R&D facility of approximately 3,000 square meters equipped with 45 million yuan in testing instruments, and pursues long-term R&D collaborations with China Pharmaceutical University and Shenyang Pharmaceutical University, supplemented by technical cooperation with Beijing Sunshine Nuohe Pharmaceutical Research Co., Ltd. Revenue is generated through direct sales via a nationwide network of field business managers, with exports to CIS (Commonwealth of Independent States) and Southeast Asian countries and active pursuit of EU market entry through China-EU dual filing and EU GMP certification. Products are sold to hospitals, clinics, pharmacies, and end-use patients across domestic and international markets.

The business model is conventional generic pharma manufacturing: priced product sales (pricing not publicly disclosed), horizontal segmentation across multiple therapeutic areas, and a multi-format portfolio targeting both chronic and acute conditions. Notable commercial assets include 10 product registrations obtained in the past five years and a product portfolio spanning cardiovascular, neurological, gastrointestinal, respiratory, anti-infective, and dermatological indications. The company holds the Internet Drug Information Service Qualification Filing (non-profit filing) and has completed carbon footprint, greenhouse gas, and clean production audits for 2024, with a 2026-revised environmental emergency response plan.

Name

Hainan Hualon Pharmaceutical

Legal name

Hainan Hualon Pharmaceutical Co., Ltd.

Website

https://hnhuanglong.com

Company type

Private

Founded year

1995

Operating status

Operating

Headcount range

1–10 employees

Short description

Hainan Hualon Pharmaceutical is a privately-held Chinese generic drug manufacturer headquartered in Hainan, producing oral, injection, topical, and inhalation formulations focused on cardiovascular, cerebrovascular, diabetes, anti-infective, and dermatological therapies for domestic and international markets.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals Manufacturing

NAICS

Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

Keywords

• Generic pharmaceutical manufacturing
• Cardiovascular drug formulations
• Injection pharmaceutical products
• Topical pharmaceutical preparations
• Oral solid dosage forms

Headquarters

HQ city

Haikou

HQ country

China

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: The company generates revenue through manufacturing and selling pharmaceutical products including oral, injection, inhalation, and external use drug formulations. Products target cardiovascular, cerebrovascular, diabetes (三高: hypertension, hyperlipidemia, hyperglycemia) areas and various therapeutic applications.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels1 record

Core offering

Hainan Hualon Pharmaceutical develops, manufactures, and distributes generic pharmaceutical formulations across four dosage form categories: oral products (tablets and granules), injections, topical/external preparations, and inhalation products. The portfolio targets cardiovascular, cerebrovascular, metabolic diseases (hypertension, hyperlipidemia, hyperglycemia), anti-infective conditions, dermatology, pain management, and gastrointestinal disorders. The company operates its own manufacturing facilities in Haikou National High-Tech Industrial Development Zone with an integrated R&D center supporting an active pipeline of nearly 30 products in development.

Product overview

Hainan Hualon Pharmaceutical is a national high-tech pharmaceutical enterprise specializing in the research, development, manufacturing, and distribution of generic pharmaceutical products. The company operates a multi-category portfolio organized into four core product lines: oral products (tablets and granules for cardiovascular, diabetes, anti-infective, and gastrointestinal conditions), injection products (for cardiovascular, pain management, antibiotics, nutritional support, and neurological applications), topical/external products (antiseptics, dermatological treatments, and feminine hygiene products), and inhalation products. The company focuses on the cardiovascular and metabolic disease space (3-High: hypertension, hyperlipidemia, hyperglycemia), antibiotics, and dermatology. Research capabilities include a 3,000 sqm R&D building with 45 million RMB in equipment, supporting generic drug development and consistency evaluations. The company has obtained 10 product registrations in five years and 8 generic drug consistency certifications, with approximately 30 products in the pipeline.

Differentiator

Problem solved

Functional benefit

Products and services

• Oral Pharmaceutical Product Line (口服产品系列) Tablets and granules for cardiovascular diseases (Valsartan, Ivabradine, Pitavastatin), diabetes (Voglibose), gastrointestinal conditions (Hydrotalcite), anti-infective applications (Ribavirin, Fluconazole, Metronidazole), and allergic conditions (Ebastine). Marketed to hospitals, clinics, and pharmacies.
• Injection Pharmaceutical Product Line (注射用产品系列) Injectable pharmaceutical formulations including cardiovascular agents (Nicorandil, Terlipressin), pain and fever management (Propacetamol, Naproxen Sodium, Lysine Acetylsalicylate, Parecoxib), neurological agents (Piracetam, Acetylglutamine), proton pump inhibitors (Omeprazole, Pantoprazole, Cimetidine), antibiotics (Aztreonam), nutritional supplements (Fructose, Invert Sugar, Alanylglutamine, Water-Soluble Vitamins), and obstetric care products (Carboprost). Marketed to hospitals and clinical settings.
• Topical/External Pharmaceutical Product Line (外用产品系列) Topical and external pharmaceutical preparations including antiseptic solutions (Benzalkonium Chloride, Povidone Iodine), dermatological treatments (Pimecrolimus Ointment for atopic dermatitis), antibiotic lotions (Amikacin Lotion), and feminine hygiene/anti-infective products (Metronidazole Chlorhexidine Lotion for bacterial vaginosis and trichomoniasis). Marketed to hospitals, clinics, and pharmacies.
• Inhalation Pharmaceutical Product Line (吸入产品系列) Dedicated inhalation pharmaceutical product series utilizing proprietary inhalation drug delivery technology. Marketed to hospitals, clinics, and respiratory care providers as part of the company's specialized therapeutic portfolio.

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered important.

• 中国药科大学 (China Pharmaceutical University)importantStrategic or Co-development PartnerEstablished long-term cooperative relationships with top domestic drug research institutions. China Pharmaceutical University provides access to latest international pharmaceutical research achievements and supports new drug R&D.
• 沈阳药科大学 (Shenyang Pharmaceutical University)importantStrategic or Co-development PartnerLong-term cooperation with Shenyang Pharmaceutical University for new drug development and technology advancement.
• 北京阳光诺和药物研究股份有限公司 (Beijing Sunshine Nuohe Pharmaceutical Research Co., Ltd.)importantTechnology or IntegrationTechnology cooperation partner for pharmaceutical research and development services.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Livzon Pharmaceutical Group: Mid-to-large Chinese pharmaceutical manufacturer with diversified generic portfolio across cardiovascular, GI, anti-infective and dermatology, plus injectable products. Comparable in therapeutic-area breadth and multi-dosage-form approach; more diversified into biologics and APIs.
• Salubris Pharmaceuticals: Shenzhen Salubris is a Chinese mid-size pharmaceutical company focused on cardiovascular and anti-infective generics, including valsartan and ARB products. Most directly comparable to Hualon given overlapping cardiometabolic generic focus, similar mid-size scale, and parallel generic consistency evaluation strategy.
• Shandong Xinhua Pharmaceutical: Chinese generic manufacturer with significant cardiovascular, anti-infective and dermatology portfolios plus international export focus. Comparable to Hualon as a multi-category Chinese generic exporter pursuing consistency evaluations, but with established EU GMP footprint.

Broad incumbents

• Shanghai Pharmaceuticals Holding: One of China's largest pharmaceutical groups spanning generics, distribution, and innovative drugs, with material cardiovascular and metabolic disease exposure. Comparable in finished-dosage-form generic manufacturing but operates at vastly larger scale with integrated distribution.
• China Resources Double-Crane Pharmaceutical: State-owned Chinese generic manufacturer with substantial cardiovascular, anti-infective, and injectable product portfolios, and active consistency evaluation pipeline. Comparable in finished-dosage-form generic strategy but operates as a SOE with broader scale and capital access.
• Yangtze River Pharmaceutical Group: One of China's largest privately-held pharma manufacturers with broad cardiometabolic generic portfolios. Comparable to Hualon in product categories (cardiovascular, anti-infective, GI) but operates at substantially greater scale with national commercial reach and broader pipeline.

Emerging players

• Yiling Pharmaceutical: Chinese pharmaceutical manufacturer with cardiovascular and metabolic disease focus plus expanding R&D pipeline. Comparable in cardiometabolic disease strategy and Chinese-domestic commercial channels; differs by stronger traditional Chinese medicine component.
• Zhuhai Rundu Pharmaceutical: Smaller Chinese pharmaceutical manufacturer with cardiovascular, anti-infective and dermatology focus. Comparable to Hualon in therapeutic mix and private mid-size profile; less developed in inhalation and international expansion.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/hainan-hualon-pharmaceutical-co-ltd

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hainan Hualon Pharmaceutical